Stock Comparison

BEAT vs JNJ

Heartbeam Inc vs Johnson & Johnson

The Verdict

BEAT takes this one.

Winner

BEAT

Heartbeam Inc

3.9

out of 10

Risk Trap

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$50M

Market Cap

$557.1B

-1.6

P/E Ratio

26.5

N/A

Profit Margin

21.8%

-571.1%

Return on Equity

26.3%

N/A

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

3.9

DVR Score

1.0

The Deep Dive

BEAT3.9/10

Heartbeam continues to possess intriguing long-term potential anchored by its innovative 3D VECG technology and FDA-cleared AIMIGo, targeting a critical and expanding cardiovascular monitoring market. The leadership has demonstrated relevant expertise and achieved regulatory milestones. However, the company's financial state remains extremely precarious with $0 revenue in Q1 2026, a substantial ne...

Full BEAT Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.